Categories: News

Vistin Pharma ASA: Invitation to Q4 2021 conference call

Oslo, Norway, 8 February 2022

Vistin Pharma ASA will release its fourth quarter 2021 results on Thursday 17th of February 2022. Vistin Pharma will host a conference call for all shareholders and interested parties on Thursday 17th of February at 08:30 CET. There will be a Q&A session following the management discussion.

The conference call will be held in English.

The fourth quarter conference call will be available via web and audio through the following access points:

Telephone conference:
Confirmation Code:…….. 7590346
International dial-In:…….. +44 (0) 2071 928338
Norway, Oslo:……………. +47 21563015
United States, New York: +1 6467413167

Webcast:
https://edge.media-server.com/mmc/p/jb9o62eq

*****

For further information, please contact:

Alexander Karlsen
CFO
+47 97053621
alexander.karlsen@vistin.com

Staff

Recent Posts

RPI Consultants Presents Annual Scholarship to Healthcare Technology Professional

BALTIMORE, Feb. 5, 2026 /PRNewswire/ -- RPI Consultants, a leading ERP implementation, optimization, and software firm…

2 minutes ago

BioPhorum announces formation of Strategic Advisory Board to accelerate industry collaboration

LONDON, Feb. 5, 2026 /PRNewswire/ -- BioPhorum, the pharmaceutical industry's most trusted collaborative network for…

2 minutes ago

BC Platforms partners with OmicsBank to expand access to large-scale real-world and multi-omics data from India and the UAE

Patient catchment now includes 187 million+ patient lives, enables advanced analytics and AI modeling for…

2 minutes ago

Electron Microscopy Market to Reach $10.3 billion, Globally, by 2034 at 8.1% CAGR: Allied Market Research

The electron microscopy market is driven by rapid advancements in nanotechnology, increase in demand for…

2 minutes ago

BioNxt Secures Innovative Chaperone Technology to Enhance Oral Thin-Film Drug Delivery

VANCOUVER, BC / ACCESS Newswire / February 5, 2026 / BioNxt Solutions Inc. ("BioNxt" or…

3 minutes ago

Pentixapharm Announces Peer-Reviewed Phase 2 Data Back Use of PENTIXAFOR as a Superior Non-invasive PET-Diagnostic for Primary Aldosteronism

In the study, [68Ga]Ga-Pentixafor PET/CT was well tolerated and demonstrated high specificity and moderate sensitivity…

3 hours ago